Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Hepatocellular Carcinoma
June 30, 2020Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.
Nexavar has been firmly established as the standard of care in advanced HCC since gaining approval in the US in 2007. However, Nexavar is forecast to steadily lose market share after the introduction of generics in 2020 (US), 2021 (EU), and 2022 (Japan). Additionally, Nexavar will face strong competition from the combination of Tecentriq and Avastin, which was the first regimen to demonstrate both superior overall survival and progression-free survival over Nexavar in the Phase III IMbrave150 study.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)|